This is a preview of subscription content, log in via an institution to check access.
Reference
Sarkar R, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory acute lymphoblastic leukemia. 54th Annual Meeting of the American Society of Clinical Oncology : (plus poster) abstr. 6610, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_224135.html
Rights and permissions
About this article
Cite this article
CAR-T cell therapy cost effective for paediatric ALL. PharmacoEcon Outcomes News 806, 4 (2018). https://doi.org/10.1007/s40274-018-5047-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5047-3